Dr. Reddy’s Laboratories has announced the termination of its distribution and promotion agreement with Novartis India Limited (NIL) for select brands in India, effective February 11, 2022. This decision follows a change in the controlling shareholding of NIL. The company will continue to commercialize the covered brands until September 30, 2026. This move aims to streamline operations and adapt to evolving market dynamics.
Distribution Agreement Terminated
Dr. Reddy’s Laboratories has formally terminated its agreement with Novartis India Limited (NIL) concerning the distribution and promotion of specific brands within the Indian market. The agreement, originally dated February 11, 2022, has been concluded due to recent changes in the controlling shareholding of NIL. This strategic decision by Dr. Reddy’s is intended to realign its commercial activities and focus on key brand portfolios.
Commercialization Period Extended
Despite the termination of the agreement, Dr. Reddy’s Laboratories will continue to manage the commercialization of the brands that were covered under the pact. This extended commercialization period will run until September 30, 2026. This allows for an orderly transition and ensures continued market availability of the affected products during this phase.
The company has duly informed the relevant stock exchanges of this development.
Source: BSE
